iPremom’s EUR 15 million seed round is a clear bet on women’s health diagnostics moving earlier in the care pathway, from symptom-led intervention to first-trimester risk screening. The syndicate mix matters: UK-based Amadeus Capital Partners leading, with Spain-based Asabys Partners and APEX Ventures participating, signals sustained cross-border appetite for clinically anchored European femtech.
Deal snapshot
Valencia-based molecular diagnostics startup iPremom has raised EUR 15 million in a seed round led by Amadeus Capital Partners, with participation from Asabys Partners and APEX Ventures. The company positions itself in the women’s health diagnostic category, focused on early detection of pregnancy complications.
Terms beyond the headline amount were not disclosed. Use of proceeds has been described at a high level as advancing early detection capabilities.
Why this round fits the current market
European health-tech funding has been bifurcating: platform-heavy, long-horizon stories are facing higher bars, while diagnostics and clinical decision support with measurable endpoints continue to attract capital. iPremom sits in the latter camp.
Multiple reports describe iPremom as a femtech or medical startup targeting early pregnancy risk detection. That focus aligns with a broader push in maternal health to reduce severe outcomes by identifying risk well before clinical deterioration, and it maps to payer and provider interest in prevention-led pathways.
The investor lineup reinforces the point. With Amadeus leading and a Spain-anchored investor (Asabys) in the syndicate, the round reads as both a cross-border validation and a local ecosystem outcome, consistent with Spain’s growing health-tech pipeline attracting non-domestic capital.
Product and clinical narrative: what is being underwritten
iPremom says its technology identifies early molecular alterations linked to pregnancy complications before symptoms appear. The company’s PREMOM clinical study is described as a prospective multicentre trial demonstrating sensitivity and specificity of circulating cell-free RNA for early screening of preeclampsia and other pregnancy complications.
The company also states that its resulting blood test can predict severe early-onset preeclampsia from the first trimester, potentially flagging risk months before symptoms emerge. If replicated at scale and translated into routine workflows, that is a strong clinical proposition in a category where timing is the constraint.
What remains to be proven, and will likely determine the next valuation step, is less about the headline clinical promise and more about execution detail:
- Clinical generalisability: performance across geographies, care settings, and patient cohorts.
- Workflow fit: how the test integrates into existing first-trimester screening routines and obstetric pathways.
- Health economics: whether earlier identification translates into reduced high-cost adverse events and defensible reimbursement.
Spain as a base, Europe as the capital pool
iPremom is based in Valencia, with an address listed in Paterna. Its materials reference support from ICEX and the European FEDER fund under the Invest in Spain program, pointing to public backing tied to Spain’s innovation ecosystem.
That public-private stack is increasingly common in European diagnostics: early non-dilutive support helps teams reach a credible clinical inflection point, then cross-border VC syndicates step in to fund the next phase.
What to watch next
- Evidence of regulatory and reimbursement pathway progress in key European markets.
- Updates on prospective clinical validation beyond the PREMOM study and any real-world deployment.
- Whether iPremom builds commercial partnerships with hospital networks, labs, or prenatal screening providers.
- Hiring signals around quality, regulatory, and commercial leadership to match the clinical ambition.
- Any clarity on go-to-market sequencing: Spain-first rollout versus multi-country expansion from day one.